Indoleamine 2,3-dioxygenase, Tregs and cancer

Current Medicinal Chemistry

Volumn 18, Issue 15, 2011, Pages 2240-2246

  Munn, D H ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Dendritic cells; Foxp3; IDO; Regulatory T cells; Tumor immunology

Indexed keywords

1 METHYL DEXTRO TRYPTOPHAN; ANTINEOPLASTIC AGENT; B7 ANTIGEN; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HALOFUGINONE; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE GCN2; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; INITIATION FACTOR 2ALPHA; INTERLEUKIN 17; INTERLEUKIN 6; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3; TRANSFER RNA; TRYPTOPHAN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CYCLE ARREST; COLORECTAL CANCER; DENDRITIC CELL; DRUG EFFICACY; DRUG POTENTIATION; EFFECTOR CELL; ENDOMETRIUM CANCER; EXPERIMENTAL NEOPLASM; HELPER CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; MELANOMA B16; NONHUMAN; NUCLEAR REPROGRAMMING; OVARY CANCER; PANCREAS CANCER; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PROSTATE CANCER; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TARGET CELL; TH17 CELL; TRYPTOPHAN METABOLISM; TUMOR GROWTH; TUMOR IMMUNOLOGY;

EID: 79957936035     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711795656045     Document Type: Article

References (117)

1. Mellor, A.L.; Munn, D.H. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat. Rev. Immunol., 2008, 8, 74-80.
2. Munn, D.H.; Mellor, A.L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest., 2007, 117, 1147-1154. (Pubitemid 46718399)
3. Ball, H.J.; Yuasa, H.J.; Austin, C.J.; Weiser, S.; Hunt, N.H. Indoleamine 2,3- dioxygenase-2; a new enzyme in the kynurenine pathway. Int J Biochem Cell Biol, 2009, 41, 467-471.
4. Munn, D.H.; Zhou, M.; Attwood, J.T.; Bondarev, I.; Conway, S.J.; Marshall, B.; Brown, C.; Mellor, A.L. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science, 1998, 281, 1191-1193. (Pubitemid 28406294)
5. Muller, A.J.; Duhadaway, J.B.; Donover, P.S.; Sutanto-Ward, E.; Prendergast, G.C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med., 2005, 11, 312-319. (Pubitemid 40460560)
6. Jasperson, L.K.; Bucher, C.; Panoskaltsis-Mortari, A.; Taylor, P.A.; Mellor, A.L.; Munn, D.H.; Blazar, B.R. Indoleamine 2,3-dioxygenase is a critical regulator of acute GVHD lethality. Blood, 2008, 111, 3257-3265.
7. Gurtner, G.J.; Newberry, R.D.; Schloemann, S.R.; McDonald, K.G.; Stenson, W.F. Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastroenterology, 2003, 125, 1762-1773. (Pubitemid 37500441)
8. Romani, L.; Fallarino, F.; De Luca, A.; Montagnoli, C.; D'Angelo, C.; Zelante, T.; Vacca, C.; Bistoni, F.; Fioretti, M.C.; Grohmann, U.; Segal, B.H.; Puccetti, P. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature, 2008, 451, 211-215.
9. Grohmann, U.; Volpi, C.; Fallarino, F.; Bozza, S.; Bianchi, R.; Vacca, C.; Orabona, C.; Belladonna, M.L.; Ayroldi, E.; Nocentini, G.; Boon, L.; Bistoni, F.; Fioretti, M.C.; Romani, L.; Riccardi, C.; Puccetti, P. Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat Med, 2007, 13, 579-586. (Pubitemid 46828479)
10. van der Marel, A.P.; Samsom, J.N.; Greuter, M.; van Berkel, L.A.; O'Toole, T.; Kraal, G.; Mebius, R.E. Blockade of IDO inhibits nasal tolerance induction. J. Immunol., 2007, 179, 894-900.
11. Grohmann, U.; Orabona, C.; Fallarino, F.; Vacca, C.; Calcinaro, F.; Falorni, A.; Candeloro, P.; Belladonna, M.L.; Bianchi, R.; Fioretti, M.C.; Puccetti, P. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol., 2002, 3, 1097-1101. (Pubitemid 35363664)
12. Mellor, A.L.; Baban, B.; Chandler, P.; Marshall, B.; Jhaver, K.; Hansen, A.; Koni, P.A.; Iwashima, M.; Munn, D.H. Cutting Edge: Induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol., 2003, 171, 1652-1655. (Pubitemid 36966447)
13. Guillonneau, C.; Hill, M.; Hubert, F.X.; Chiffoleau, E.; Herve, C.; Li, X.L.; Heslan, M.; Usal, C.; Tesson, L.; Menoret, S.; Saoudi, A.; Le Mauff, B.; Josien, R.; Cuturi, M.C.; Anegon, I. CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase. J. Clin. Invest., 2007, 117, 1096-1106. (Pubitemid 46556766)
14. Swanson, K.A.; Zheng, Y.; Heidler, K.M.; Mizobuchi, T.; Wilkes, D.S. CDllc+ cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenase. Am. J. Respir. Cell Mol. Biol., 2004, 30, 311-318. (Pubitemid 38315383)
15. Liu, H.; Liu, L.; Fletcher, B.S.; Visner, G.A. Novel action of indoleamine 2,3-dioxygenase attenuating acute lung allograft injury. Am. J. Respir. Crit. Care Med., 2006, 173, 566-572.
16. Fallarino, F.; Vacca, C.; Orabona, C.; Belladonna, M.L.; Bianchi, R.; Marshall, B.; Keskin, D.B.; Mellor, A.L.; Fioretti, M.C.; Grohmann, U.; Puccetti, P. Functional expression of indoleamine 2,3-dioxygenase by murine CD8alpha(+) dendritic cells. Int. Immunol., 2002, 14(1), 65-68. (Pubitemid 34083398)
17. Munn, D.H.; Sharma, M.D.; Hou, D.; Baban, B.; Lee, J.R.; Antonia, S.J.; Messina, J.L.; Chandler, P.; Koni, P.A.; Mellor, A. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumordraining lymph nodes. J. Clin. Invest., 2004, 114, 280-290. (Pubitemid 39071633)
18. Baban, B.; Hansen, A.; Chandler, P.; Manlapat, A.; Bingaman, A.; Kahler, D.; Munn, D.; Mellor, A. A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type 1 interferon-signaling following B7 ligation. Int. Immunol., 2005, 17, 909-919. (Pubitemid 41417958)
19. Mellor, A.L.; Baban, B.; Chandler, P.R.; Manlapat, A.; Kahler, D.J.; Munn, D.H. Cutting Edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN type 1 signaling. J. Immunol., 2005, 175, 5601-5605. (Pubitemid 41508038)
20. Hayashi, T.; Beck, L.; Rossetto, C.; Gong, X.; Takikawa, O.; Takabayashi, K.; Broide, D.H.; Carson, D.A.; Raz, E. Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J. Clin. Invest., 2004, 114, 270-279. (Pubitemid 39071632)
21. Desvignes, L.; Ernst, J.D. Interferon-gamma-responsive nonhematopoietic cells regulate the immune response to Mycobacterium tuberculosis. Immunity, 2009, 31, 974-985.
22. Cuffy, M.C.; Silverio, A.M.; Qin, L.; Wang, Y.; Eid, R.; Brandacher, G.; Lakkis, F.G.; Fuchs, D.; Pober, J.S.; Tellides, G. Induction of indoleamine 2,3-dioxygenase in vascular smooth muscle cells by interferon-gamma contributes to medial immunoprivilege. J Immunol, 2007, 179, 5246-5254.
23. Muller, A.J.; Sharma, M.D.; Chandler, P.R.; DuHadaway, J.B.; Everhart, M.E.; Johnson, B.A.I.; Kahler, D.J.; Pihkala, J.; Soler, A.P.; Munn, D.H.; Prendergast, G.C.; Mellor, A.L. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc. Natl. Acad. Sci. USA, 2008, 105, 17073-17078.
24. Munn, D.H.; Sharma, M.D.; Baban, B.; Harding, H.P.; Zhang, Y.; Ron, D.; Mellor, A.L. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity, 2005, 22, 633-642. (Pubitemid 40719198)
25. Hwu, P.; Du, M.X.; Lapointe, R.; Do, M.; Taylor, M.W.; Young, H.A. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J. Immunol., 2000, 164(7), 3596-3599. (Pubitemid 30169812)
26. Vacca, C.; Fallarino, F.; Perruccio, K.; Orabona, C.; Bianchi, R.; Gizzi, S.; Velardi, A.; Fioretti, M.C.; Puccetti, P.; Grohmann, U. CD40 ligation prevents onset of tolerogenic properties in human dendritic cells treated with CTLA-4-Ig. Microbes Infect., 2005, 7, 1040-1048. (Pubitemid 40982673)
27. Orabona, C.; Puccetti, P.; Vacca, C.; Bicciato, S.; Luchini, A.; Fallarino, F.; Bianchi, R.; Velardi, E.; Perruccio, K.; Velardi, A.; Bronte, V.; Fioretti, M.C.; Grohmann, U. Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood, 2006, 107(7), 2846-2854.
28. Beutelspacher, S.C.; Pillai, R.; Watson, M.P.; Tan, P.H.; Tsang, J.; McClure, M.O.; George, A.J.; Larkin, D.F. Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by overexpression. Eur. J. Immunol., 2006, 36, 690-700.
29. Braun, D.; Longman, R.S.; Albert, M.L. A two step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic cell maturation. Blood, 2005, 106(7), 2375-2381. (Pubitemid 41510810)
30. Wobser, M.; Voigt, H.; Houben, R.; Eggert, A.O.; Freiwald, M.; Kaemmerer, U.; Kaempgen, E.; Schrama, D.; Becker, J.C. Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression. Can. Immunol. Immunother., 2007, 56, 1017-1024. (Pubitemid 46675300)
31. Rutella, S.; Bonanno, G.; Procoli, A.; Mariotti, A.; de Ritis, D.G.; Curti, A.; Danese, S.; Pessina, G.; Pandolfi, S.; Natoni, F.; Di Febo, A.; Scambia, G.; Manfredini, R.; Salati, S.; Ferrari, S.; Pierelli, L.; Leone, G.; Lemoli, R.M. Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood, 2006, 108, 218-227. (Pubitemid 43990632)
32. Duluc, D.; Delneste, Y.; Tan, F.; Moles, M.P.; Grimaud, L.; Lenoir, J.; Preisser, L.; Anegon, I.; Catala, L.; Ifrah, N.; Descamps, P.; Gamelin, E.; Gascan, H.; Hebbar, M.; Jeannin, P. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associatedmacrophage- like cells. Blood, 2007, 110, 4319-4330. (Pubitemid 351377797)
33. Brenk, M.; Scheler, M.; Koch, S.; Neumann, J.; Takikawa, O.; Hacker, G.; Bieber, T.; von Bubnoff, D. Tryptophan deprivation induces inhibitory receptors ILT3 and ILT4 on dendritic cells favoring the induction of human CD4+CD25+ Foxp3+ T regulatory cells. J Immunol, 2009, 183, 145-154.
34. Beutelspacher, S.C.; Tan, P.H.; McClure, M.O.; Larkin, D.F.; Lechler, R.I.; George, A.J. Expression of indoleamine 2,3-dioxygenase (IDO) by endothelial cells: implications for the control of alloresponses. Am. J. Transplant. , 2006, 6, 1320-1330. (Pubitemid 44030315)
35. Boasso, A.; Herbeuval, J.P.; Hardy, A.W.; Anderson, S.A.; Dolan, M.J.; Fuchs, D.; Shearer, G.M. HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood, 2007, 109, 3351-3359. (Pubitemid 46572523)
36. Chung, D.J.; Rossi, M.; Romano, E.; Ghith, J.; Yuan, J.; Munn, D.H.; Young, J.W. Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood, 2009, 114, 555-563.
37. Manches, O.; Munn, D.; Fallahi, A.; Lifson, J.; Chaperot, L.; Plumas, J.; Bhardwaj, N. HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. J. Clin. Invest., 2008, 118, 3431-3439.
38. Chen, W.; Liang, X.; Peterson, A.J.; Munn, D.H.; Blazar, B.R. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J. Immunol., 2008, 181, 5396-5404.
39. Munn, D.H.; Shafizadeh, E.; Attwood, J.T.; Bondarev, I.; Pashine, A.; Mellor, A.L. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med., 1999, 189, 1363-1372. (Pubitemid 29227522)
40. Terness, P.; Chuang, J.J.; Bauer, T.; Jiga, L.; Opelz, G. Regulation of human auto- and alloreactive T cells by indoleamine 2,3-dioxygenase (IDO)- producing dendritic cells: too much ado about IDO? Blood, 2005, 105, 2480-2486. (Pubitemid 40387049)
41. Munn, D.H.; Sharma, M.D.; Lee, J.R.; Jhaver, K.G.; Johnson, T.S.; Keskin, D.B.; Marshall, B.; Chandler, P.; Antonia, S.J.; Burgess, R.; Slingluff, C.L.; Mellor, A.L. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science, 2002, 297, 1867-1870. (Pubitemid 35024345)
42. Munn, D.H.; Sharma, M.D.; Mellor, A.L. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J. Immunol., 2004, 172, 4100-4110. (Pubitemid 38375222)
43. Curti, A.; Pandolfi, S.; Valzasina, B.; Aluigi, M.; Isidori, A.; Ferri, E.; Salvestrini, V.; Bonanno, G.; Rutella, S.; Durelli, I.; Horenstein, A.L.; Fiore, F.; Massaia, M.; Colombo, M.P.; Baccarani, M.; Lemoli, R.M. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood, 2007, 109, 2871-2877. (Pubitemid 46482083)
44. Uyttenhove, C.; Pilotte, L.; Theate, I.; Stroobant, V.; Colau, D.; Parmentier, N.; Boon, T.; Van Den Eynde, B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3- dioxygenase. Nat. Med., 2003, 9, 1269-1274. (Pubitemid 37279849)
45. Brody, J.R.; Costantino, C.L.; Berger, A.C.; Sato, T.; Lisanti, M.P.; Yeo, C.J.; Emmons, R.V.; Witkiewicz, A.K. Expression of indoleamine 2,3- dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle, 2009, 8, 1930-1934.
46. Polak, M.E.; Borthwick, N.J.; Gabriel, F.G.; Johnson, P.; Higgins, B.; Hurren, J.; McCormick, D.; Jager, M.J.; Cree, I.A. Mechanisms of local immunosuppression in cutaneous melanoma. Br J Cancer, 2007, 96, 1879-1887. (Pubitemid 46912012)
47. Witkiewicz, A.; Williams, T.K.; Cozzitorto, J.; Durkan, B.; Showalter, S.L.; Yeo, C.J.; Brody, J.R. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J Am Coll Surg, 2008, 206, 849-854; discussion 854-846.
48. Witkiewicz, A.K.; Costantino, C.L.; Metz, R.; Muller, A.J.; Prendergast, G.C.; Yeo, C.J.; Brody, J.R. Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg, 2009, 208, 781-787; discussion 787-789.
49. Qian, F.; Villella, J.; Wallace, P.K.; Mhawech-Fauceglia, P.; Tario, J.D. Jr.; Andrews, C.; Matsuzaki, J.; Valmori, D.; Ayyoub, M.; Frederick, P.J.; Beck, A.; Liao, J.; Cheney, R.; Moysich, K.; Lele, S.; Shrikant, P.; Old, L.J.; Odunsi, K. Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase-Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer. Cancer Res., 2009.
50. Chamuleau, M.E.; van de Loosdrecht, A.A.; Hess, C.J.; Janssen, J.J.; Zevenbergen, A.; Delwel, R.; Valk, P.J.; Lowenberg, B.; Ossenkoppele, G.J. High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome. Haematologica, 2008, 93, 1894-1898.
51. Corm, S.; Berthon, C.; Imbenotte, M.; Biggio, V.; Lhermitte, M.; Dupont, C.; Briche, I.; Quesnel, B. Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma. Leuk. Res., 2009, 33, 490-494.
52. Brandacher, G.; Perathoner, A.; Ladurner, R.; Schneeberger, S.; Obrist, P.; Winkler, C.; Werner, E.R.; Werner-Felmayer, G.; Weiss, H.G.; Gobel, G.; Margreiter, R.; Konigsrainer, A.; Fuchs, D.; Amberger, A. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin. Cancer Res., 2006, 12(4), 1144-1151. (Pubitemid 43342502)
53. Huang, A.; Fuchs, D.; Widner, B.; Glover, C.; Henderson, D.C.; Allen- Mersh, T.G. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br. J. Cancer, 2002, 86(11), 1691-1696. (Pubitemid 34712909)
54. Feder-Mengus, C.; Wyler, S.; Hudolin, T.; Ruszat, R.; Bubendorf, L.; Chiarugi, A.; Pittelli, M.; Weber, W.P.; Bachmann, A.; Gasser, T.C.; Sulser, T.; Heberer, M.; Spagnoli, G.C.; Provenzano, M. High expression of indoleamine 2,3-dioxygenase gene in prostate cancer. Eur J Cancer, 2008, 44, 2266-2275.
55. Ino, K.; Yoshida, N.; Kajiyama, H.; Shibata, K.; Yamamoto, E.; Kidokoro, K.; Takahashi, N.; Terauchi, M.; Nawa, A.; Nomura, S.; Nagasaka, T.; Takikawa, O.; Kikkawa, F. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br. J. Cancer, 2006, 95, 1555-1561. (Pubitemid 44863359)
56. Ino, K.; Yamamoto, E.; Shibata, K.; Kajiyama, H.; Yoshida, N.; Terauchi, M.; Nawa, A.; Nagasaka, T.; Takikawa, O.; Kikkawa, F. Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumorinfiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin Cancer Res, 2008, 14, 2310-2317. (Pubitemid 351551062)
57. Okamoto, A.; Nikaido, T.; Ochiai, K.; Takakura, S.; Saito, M.; Aoki, Y.; Ishii, N.; Yanaihara, N.; Yamada, K.; Takikawa, O.; Kawaguchi, R.; Isonishi, S.; Tanaka, T.; Urashima, M. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin. Cancer Res., 2005, 11(16), 6030-6039. (Pubitemid 41170335)
58. Lee, J.R.; Dalton, R.R.; Messina, J.L.; Sharma, M.D.; Smith, D.M.; Burgess, R.E.; Mazzella, F.; Antonia, S.J.; Mellor, A.L.; Munn, D.H. Pattern of recruitment of immunoregulatory antigen presenting cells in malignant melanoma. Lab. Invest., 2003, 83, 1457-1466. (Pubitemid 37267829)
59. Huang, A.Y.; Golumbek, P.; Ahmadzadeh, M.; Jaffee, E.; Pardoll, D.; Levitsky, H. Role of bone marrow-derived cells in presenting MHC class Irestricted tumor antigens. Science, 1994, 264, 961-965. (Pubitemid 24196166)
60. Sotomayor, E.M.; Borrello, I.; Rattis, F.M.; Cuenca, A.G.; Abrams, J.; Staveley-O'Carroll, K.; Levitsky, H.I. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood, 2001, 98(4), 1070-1077.
61. Hildner, K.; Edelson, B.T.; Purtha, W.E.; Diamond, M.; Matsushita, H.; Kohyama, M.; Calderon, B.; Schraml, B.U.; Unanue, E.R.; Diamond, M.S.; Schreiber, R.D.; Murphy, T.L.; Murphy, K.M. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science, 2008, 322, 1097-1100.
62. Cochran, A.J.; Huang, R.R.; Lee, J.; Itakura, E.; Leong, S.P.; Essner, R. Tumour-induced immune modulation of sentinel lymph nodes. Nat. Rev. Immunol., 2006, 6, 659-670. (Pubitemid 44298215)
63. Sharma, M.D.; Baban, B.; Chandler, P.; Hou, D.Y.; Singh, N.; Yagita, H.; Azuma, M.; Blazar, B.R.; Mellor, A.L.; Munn, D.H. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest., 2007, 117, 2570-2582. (Pubitemid 47494358)
64. Darrasse-Jeze, G.; Bergot, A.S.; Durgeau, A.; Billiard, F.; Salomon, B.L.; Cohen, J.L.; Bellier, B.; Podsypanina, K.; Klatzmann, D. Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. J Clin Invest, 2009.
65. Quezada, S.A.; Peggs, K.S.; Simpson, T.R.; Shen, Y.; Littman, D.R.; Allison, J.P. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med, 2008, 205, 2125-2138.
66. Ercolini, A.M.; Ladle, B.H.; Manning, E.A.; Pfannenstiel, L.W.; Armstrong, T.D.; Machiels, J.P.; Bieler, J.G.; Emens, L.A.; Reilly, R.T.; Jaffee, E.M. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J. Exp. Med., 2005, 201(10), 1591-1602. (Pubitemid 40723662)
67. Curiel, T.J. Regulatory T cells and treatment of cancer. Curr. Opin. Immunol., 2008, 20, 241-246.
68. Chon, S.Y.; Hassanain, H.H.; Gupta, S.L. Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in intereron-α- inducible expression of human indoleamine 2,3-dioxygenase gene. J. Biol. Chem., 1996, 271, 17247-17252. (Pubitemid 26244281)
69. Dai, W.; Gupta, S.L. Regulation of indoleamine 2,3-dioxygenase gene expression in human fibroblasts by interferon-α. The Journal of Biological Chemistry, 1990, 265, 19871-19877.
70. Ozaki, Y.; Edelstein, M.P.; Duch, D.S. Induction of indoleamine 2,3- dioxygenase: a mechanism of the antitumor activity of interferon gamma. Proc. Natl. Acad. Sci. USA, 1988, 85, 1242-1246. (Pubitemid 18073985)
71. Fallarino, F.; Asselin-Paturel, C.; Vacca, C.; Bianchi, R.; Gizzi, S.; Fioretti, M.C.; Trinchieri, G.; Grohmann, U.; Puccetti, P. Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. J. Immunol., 2004, 173, 3748-3754. (Pubitemid 39280736)
72. Munn, D.H.; Mellor, A.L.; Rossi, M.; Young, J.W. Dendritic cells have the option to express IDO-mediated suppression or not. Blood, 2005, 105, 2618. (Pubitemid 40387070)
73. Orabona, C.; Pallotta, M.T.; Volpi, C.; Fallarino, F.; Vacca, C.; Bianchi, R.; Belladonna, M.L.; Fioretti, M.C.; Grohmann, U.; Puccetti, P. SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc. Natl. Acad. Sci. USA, 2008, 105, 20828-20833.
74. Fallarino, F.; Grohmann, U.; Hwang, K.W.; Orabona, C.; Vacca, C.; Bianchi, R.; Belladonna, M.L.; Fioretti, M.C.; Alegre, M.L.; Puccetti, P. Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol., 2003, 4, 1206-1212. (Pubitemid 37547898)
75. Puccetti, P.; Grohmann, U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat. Rev. Immunol., 2007, 7, 817-823. (Pubitemid 47480306)
76. Friedline, R.H.; Brown, D.S.; Nguyen, H.; Kornfeld, H.; Lee, J.; Zhang, Y.; Appleby, M.; Der, S.D.; Kang, J.; Chambers, C.A. CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med, 2009, 206, 421-434.
77. Onodera, T.; Jang, M.H.; Guo, Z.; Yamasaki, M.; Hirata, T.; Bai, Z.; Tsuji, N.M.; Nagakubo, D.; Yoshie, O.; Sakaguchi, S.; Takikawa, O.; Miyasaka, M. Constitutive expression of IDO by dendritic cells of mesenteric lymph nodes: functional involvement of the CTLA-4/B7 and CCL22/CCR4 interactions. J Immunol, 2009, 183, 5608-5614.
78. Fallarino, F.; Grohmann, U.; You, S.; McGrath, B.C.; Cavener, D.R.; Vacca, C.; Orabona, C.; Bianchi, R.; Belladonna, M.L.; Volpi, C.; Santamaria, P.; Fioretti, M.C.; Puccetti, P. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol., 2006, 176(11), 6752-6761. (Pubitemid 43787857)
79. Park, M.J.; Min, S.Y.; Park, K.S.; Cho, Y.G.; Cho, M.L.; Jung, Y.O.; Park, H.S.; Chang, S.H.; Cho, S.G.; Min, J.K.; Park, S.H.; Kim, H.Y. Indoleamine 2,3-dioxygenase-expressing dendritic cells are involved in the generation of CD4+CD25+ regulatory T cells in Peyer's patches in an orally tolerized, collagen-induced arthritis mouse model. Arthritis Res. Ther., 2008, 10, R11.
80. Kwon, H.K.; Lee, C.G.; So, J.S.; Chae, C.S.; Hwang, J.S.; Sahoo, A.; Nam, J.H.; Rhee, J.H.; Hwang, K.C.; Im, S.H. Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders. Proc. Natl. Acad. Sci. USA, 2010, 107, 2159-2164.
81. Jurgens, B.; Hainz, U.; Fuchs, D.; Felzmann, T.; Heitger, A. Interferongamma- triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells. Blood, 2009, 114, 3235-3243.
82. Valzasina, B.; Piconese, S.; Guiducci, C.; Colombo, M.P. Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res., 2006, 66(8), 4488-4495.
83. Wang, L.; Pino-Lagos, K.; de Vries, V.C.; Guleria, I.; Sayegh, M.H.; Noelle, R.J. Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci U S A, 2008, 105, 9331-9336.
84. Zhou, G.; Levitsky, H.I. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J. Immunol., 2007, 178, 2155-2162. (Pubitemid 46233413)
85. Wang, H.Y.; Peng, G.; Guo, Z.; Shevach, E.M.; Wang, R.F. Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigenspecific CD4+ regulatory T cells. J. Immunol., 2005, 174(5), 2661-2670. (Pubitemid 40279680)
86. Vence, L.; Palucka, A.K.; Fay, J.W.; Ito, T.; Liu, Y.J.; Banchereau, J.; Ueno, H. Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA, 2007, 104, 20884-20889.
87. Bonertz, A.; Weitz, J.; Pietsch, D.H.; Rahbari, N.N.; Schlude, C.; Ge, Y.; Juenger, S.; Vlodavsky, I.; Khazaie, K.; Jaeger, D.; Reissfelder, C.; Antolovic, D.; Aigner, M.; Koch, M.; Beckhove, P. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest, 2009, 119, 3311-3321.
88. Baban, B.; Chandler, P.R.; Sharma, M.D.; Pihkala, J.; Koni, P.A.; Munn, D.H.; Mellor, A.L. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol, 2009, 183, 2475-2483.
89. O'Shea, J.J.; Paul, W.E. Mechanisms Underlying Lineage Commitment and Plasticity of Helper CD4+ T Cells. Science, 2010, 327, 1098-1102.
90. Williams, L.M.; Rudensky, A.Y. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol, 2007, 8, 277-284. (Pubitemid 46745377)
91. Yang, X.O.; Nurieva, R.; Martinez, G.J.; Kang, H.S.; Chung, Y.; Pappu, B.P.; Shah, B.; Chang, S.H.; Schluns, K.S.; Watowich, S.S.; Feng, X.H.; Jetten, A.M.; Dong, C. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity, 2008, 29, 44-56.
92. Zhou, L.; Chong, M.M.; Littman, D.R. Plasticity of CD4+ T cell lineage differentiation. Immunity, 2009, 30, 646-655.
93. Duarte, J.H.; Zelenay, S.; Bergman, M.L.; Martins, A.C.; Demengeot, J. Natural Treg cells spontaneously differentiate into pathogenic helper cells in lymphopenic conditions. Eur. J. Immunol., 2009, 39, 948-955.
94. Komatsu, N.; Mariotti-Ferrandiz, M.E.; Wang, Y.; Malissen, B.; Waldmann, H.; Hori, S. Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc. Natl. Acad. Sci. USA, 2009, 106, 1903-1908.
95. Radhakrishnan, S.; Cabrera, R.; Schenk, E.L.; Nava-Parada, P.; Bell, M.P.; Van Keulen, V.P.; Marler, R.J.; Felts, S.J.; Pease, L.R. Reprogrammed FoxP3+ T regulatory cells become IL-17+ antigen-specific autoimmune effectors in vitro and in vivo. J Immunol, 2008, 181, 3137-3147.
96. Osorio, F.; LeibundGut-Landmann, S.; Lochner, M.; Lahl, K.; Sparwasser, T.; Eberl, G.; Reis e Sousa, C. DC activated via dectin-1 convert Treg into IL-17 producers. Eur. J. Immunol., 2008, 38, 3274-3281.
97. Oldenhove, G.; Bouladoux, N.; Wohlfert, E.A.; Hall, J.A.; Chou, D.; Dos Santos, L.; O'Brien, S.; Blank, R.; Lamb, E.; Natarajan, S.; Kastenmayer, R.; Hunter, C.; Grigg, M.E.; Belkaid, Y. Decrease of Foxp3(+) Treg Cell Number and Acquisition of Effector Cell Phenotype during Lethal Infection. Immunity, 2009.
98. Zhou, X.; Bailey-Bucktrout, S.L.; Jeker, L.T.; Penaranda, C.; Martinez- Llordella, M.; Ashby, M.; Nakayama, M.; Rosenthal, W.; Bluestone, J.A. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat. Immunol., 2009.
99. Sharma, M.D.; Hou, D.Y.; Liu, Y.; Koni, P.A.; Metz, R.; Chandler, P.; Mellor, A.L.; He, Y.; Munn, D.H. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood, 2009, 113, 6102-6111.
100. Pasare, C.; Medzhitov, R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science, 2003, 299, 1033-1036. (Pubitemid 36222922)
101. Metz, R.; Duhadaway, J.B.; Kamasani, U.; Laury-Kleintop, L.; Muller, A.J.; Prendergast, G.C. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res, 2007, 67, 7082-7087. (Pubitemid 47206533)
102. Wek, R.C.; Jiang, H.Y.; Anthony, T.G. Coping with stress: eIF2 kinases and translational control. Biochem. Soc. Trans., 2006, 34, 7-11. (Pubitemid 43235522)
103. Harding, H.P.; Novoa, I.; Zhang, Y.; Zeng, H.; Wek, R.; Schapira, M.; Ron, D. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol. Cell., 2000, 6(5), 1099-1108.
104. Forouzandeh, F.; Jalili, R.B.; Germain, M.; Duronio, V.; Ghahary, A. Differential immunosuppressive effect of indoleamine 2,3-dioxygenase (IDO) on primary human CD4+ and CD8+ T cells. Mol Cell Biochem, 2008, 309, 1-7.
105. Rodriguez, P.C.; Quiceno, D.G.; Ochoa, A.C. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood, 2007, 109, 1568-1573. (Pubitemid 46239590)
106. Jalili, R.B.; Forouzandeh, F.; Moeenrezakhanlou, A.; Rayat, G.R.; Rajotte, R.V.; Uludag, H.; Ghahary, A. Mouse pancreatic islets are resistant to indoleamine 2,3 dioxygenase-induced general control nonderepressible-2 kinase stress pathway and maintain normal viability and function. Am J Pathol, 2009, 174, 196-205.
107. Blander, J.M.; Amsen, D. Immunology. Amino acid addiction. Science, 2009, 324, 1282-1283.
108. Sundrud, M.S.; Koralov, S.B.; Feuerer, M.; Calado, D.P.; Kozhaya, A.E.; Rhule-Smith, A.; Lefebvre, R.E.; Unutmaz, D.; Mazitschek, R.; Waldner, H.; Whitman, M.; Keller, T.; Rao, A. Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Science, 2009, 324, 1334-1338.
109. Belladonna, M.L.; Orabona, C.; Grohmann, U.; Puccetti, P. TGF-beta and kynurenines as the key to infectious tolerance. Trends Mol. Med., 2009, 15, 41-49.
110. Hayashi, T.; Mo, J.H.; Gong, X.; Rossetto, C.; Jang, A.; Beck, L.; Elliott, G.I.; Kufareva, I.; Abagyan, R.; Broide, D.H.; Lee, J.; Raz, E. 3- Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis. Proc Natl Acad Sci U S A, 2007, 104, 18619-18624. (Pubitemid 350210746)
111. Marshall, N.B.; Kerkvliet, N.I. Dioxin and immune regulation: emerging role of aryl hydrocarbon receptor in the generation of regulatory T cells. Ann N Y Acad Sci, 2010, 1183, 25-37.
112. Colombo, M.P.; Piconese, S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer, 2007, 7, 880-887. (Pubitemid 350006256)
113. Hou, D.Y.; Muller, A.J.; Sharma, M.D.; Duhadaway, J.B.; Banerjee, T.; Johnson, M.; Mellor, A.L.; Prendergast, G.C.; Munn, D.H. Inhibition of IDO in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with anti-tumor responses. Cancer Res., 2007, 67, 792-801. (Pubitemid 46192220)
114. Soliman, H.H.; Antonia, S.J.; Sullivan, D.; Vanahanian, N.; Link, C. Overcoming tumor antigen anergy in human malignancies using the novel indeolamine 2,3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-Dtryptophan (1MT). J. Clin. Oncol., 2009, 27((meeting abstracts)), 3004.
115. Muller, A.J.; Scherle, P.A. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat. Rev. Cancer, 2006, 6, 613-625. (Pubitemid 44140859)
116. Muller, A.J.; Duhadaway, J.B.; Jaller, D.; Curtis, P.; Metz, R.; Prendergast, G.C. Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate. Cancer Res., 2010, 70, 1845-1853.
117. Liu, X.; Shin, N.; Koblish, H.K.; Yang, G.; Wang, Q.; Wang, K.; Leffet, L.; Hansbury, M.J.; Thomas, B.; Rupar, M.; Waeltz, P.; Bowman, K.J.; Polam, P.; Sparks, R.B.; Yue, E.W.; Li, Y.; Wynn, R.; Fridman, J.S.; Burn, T.C.; Combs, A.P.; Newton, R.C.; Scherle, P.A. Selective inhibition of indoleamine 2,3-dioxygenase (IDO1) effectively regulates mediators of antitumor immunity. Blood, 2010.